无容量
医学
不利影响
皮疹
内科学
癌症
外科
肿瘤科
胃肠病学
免疫疗法
作者
Hideaki Suematsu,Kazuki Kano,Takanobu Yamada,Itaru Hashimoto,Hayato Watanabe,Kosuke Takahashi,Mamoru Watanabe,Kei Hayashi,Yoshihiro Kaneta,Mitsuhiro Furuta,Yasuhiro Inokuchi,Nozomu Machida,Toru Aoyama,Hiroshi Takahashi,Norio Yukawa,Yasushi Rino,Munetaka Masuda,Takashi Ogata,Takashi Oshima
出处
期刊:Anticancer Research
[Anticancer Research USA Inc.]
日期:2022-02-26
卷期号:42 (3): 1535-1540
被引量:2
标识
DOI:10.21873/anticanres.15626
摘要
To evaluate the impact of development of nivolumab monotherapy-induced immune-related adverse events (irAEs) and continuing nivolumab with irAEs on the survival of patients with gastric cancer (GC).Patients with unresectable advanced GC and recurrence after curative resection who received nivolumab monotherapy were included in the study. Survival was compared between patients who did and did not develop irAEs, and between those who continued and discontinued treatment due to irAEs.Of 110 GC patients, 22 developed irAEs. Grade ≥3 IrAEs included rash and diarrhoea associated with enteritis. Progression-free and overall survival (OS) were significantly better in patients with irAEs than in those without. The overall survival of patients who continued treatment despite irAEs was better than that of those who discontinued treatment.irAE development was associated with better survival in patients with GC who received nivolumab monotherapy. Continuing nivolumab with appropriate treatment in GC patients with irAEs may improve survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI